

Please amend the subject application as follows:

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

1. (Currently Amended) A composition which comprises:
  - (a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside derivative which comprises a converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and to ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside; an immunogenic protein,
  - (b) QS-21; a carbohydrate derived from the bark of a Quillaja saponaria Molina tree, and
  - (c) a pharmaceutically acceptable carrier, wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the

Applicants: Philip O. Livingston et al.

Serial No.: 09/534,711

Filed: March 24, 2000

Page 3

~~amounts of such conjugate and QS-21 are each present in the composition in an amount such adjuvant being effective to stimulate or enhance antibody production in a subject.~~ [[,]]

~~wherein, in the conjugate the ganglioside derivative is conjugated to the immunogenic protein through a ceramide portion of the ganglioside.~~

2.-5. (Cancelled)

6. (Currently Amended) The composition of claim 1, wherein the amount of the conjugate ganglioside is ~~an amount~~ between about 3  $\mu$ g and about 100  $\mu$ g.

7. (Currently Amended) The composition of claim 5 1, wherein the amount of QS-21 is ~~an amount~~ between about 30  $\mu$ g and about 100  $\mu$ g.

8. (Previously Presented) The composition of claim 1, wherein the subject is a human.

9.-10. (Cancelled)

11. (Currently Amended) A method of enhancing antibody production in a subject which comprises administering to the subject an effective antibody producing amount of ~~the~~ a composition of ~~claim 1~~, comprising:

(a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside which comprises a

Applicants: Philip O. Livingston et al.

Serial No.: 09/534,711

Filed: March 24, 2000

Page 4

converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;

(b) QS-21; and

(c) a pharmaceutically acceptable carrier, wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the conjugate and QS-21 are each present in the composition in an amount effective to stimulate or enhance antibody production in a subject. so as to thereby enhance antibody production in the subject.

12.-13. (Cancelled)

14. (Currently Amended) A method of treating a small cell lung cancer in a subject which comprises administering to the subject an effective small cell lung cancer treating amount of a ~~the~~ composition of claim 1, comprising:

(a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside which comprises a

Applicants: Philip O. Livingston et al.

Serial No.: 09/534,711

Filed: March 24, 2000

Page 5

converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;

(b) QS-21; and

(c) a pharmaceutically acceptable carrier, wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the conjugate and QS-21 are each present in the composition in an amount effective to ~~so as to~~ thereby treat the small cell lung cancer in the subject.

15.-16. (Cancelled)